Reduxin Light Application Method

Литература

1. Lenz М, Richter Т, Mühlhauser I. The Morbidity and Mortality Associated With Overweight and Obesity in Adulthood. A Systematic Review.DeutschesÄrzteblatt International DtschArzteblInt 2009;106(40):641-8.

2. Бугрова CA, Плохая AA. Лечение ожирения: современные аспекты. РМЖ. 2000;24(9):1140-6.

3. Chin SF, Liu W, Storkson JM, Ha YL, Pariza MW. Dietary sources of conjugated dienoic isomers of linoleic acid, a newly recognised class of anticarcinogens.J Food Compos Anal. 1992;5:185-97.

4. Pariza MW. Perspective on the safety and effectiveness of conjugated linoleic acid.Am J ClinNutr. 2004;79 (Suppl):1132S-6S.

5. Park Y, Albright KJ, Liu W, Storkson JM, Cook ME, Pariza MW. Effect of conjugated linoleic acid on body composition in mice.Lipids. 1997;32:853-8.

6. de Deckere EA, van Amelsvoort JM, McNeill GP, Jones P. Effects of conjugated linoleic acid (CLA) isomers on lipid levels and peroxisome proliferation in the hamster. Br J Nutr. 1999;82:309-17.

7. Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW. Evidence that the trans-10,cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids. 1999;34:235-41.

8. Gavino VC, Gavino G, Leblanc MJ, Tuchweber B. An isomeric mixture of conjugated linoleic acids but not pure cis-9, trans-11-octadecadienoic acid affects body weight gain and plasma lipids in hamsters. J Nutr. 2000;130:27-9.

9. Pariza MW, Park Y, Cook ME. The biologically active isomers of conjugated linoleic acid.Prog Lipid Res. 2001;40:283-98.

10. Whigham Leah D, Watras Abigail C, Schoeller, Dale A. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J ClinNutr. 2007;85:1203-11.

11. Blankson H, Stakkestad JA, Fagerton H, Thom E, Wadstein J, GudmundsenO. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr. 2000;130:2943-8.

12. Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, et al. Conjugated linoleic acid supplementation for 1 у reduces body fat mass in healthy overweight humans. Am J ClinNutr. 2004;79:1118-25.

13. Mougios V, Matsakas A, Petridou A, Ring S, Sagredos A, Melissopoulou A, et al. Effect of supplementation with conjugated linoleic acid on human serum lipids and body fat. J Nutr.Biochem. 2001;12:585-94.

14. Smedman A, Vessby B. Conjugated linoleic acid supplementation in humans-metabolic effects. Lipids. 2001;36:773-81.

15. Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, et al. Six months supplementation with conjugated linoleic acid (CLA) induces regional-specific fat mass decreases in overweight and obese. Br J Nutr. 2007;97:50-60.

16. Watras AC, Buchholz AC, Close RN, Zhang Z, Schoeller DA. The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain.Int J Obesity. 2007;31:481-7.

17. Pinkoski C, Chilibeck PD, Candow DG, Esliger D, Ewaschuk JB, Facci M, et al. The effects of conjugated linoleic acid supplementation during resistance training.Med Sci Sports.Exerc. 2006;38:339-48.

18. Berven G, Bye A, Hals O, et al. Safety of conjugated linoleic acid (CLA) in overweight or obese human volunteers. Eur J Lipid Sci Technol. 2000;102:455-62.

19. Riserus U, Arner P, Brismar K, Vessby B. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. Diabetes Care. 2002;25:1516-21.

20. Malpuech-Brugere C, Verboeket-van de Venne WP, Mensink RP, Arnal MA, Morio B, Brandolini M, et al. Effects of two conjugated linoleic acid isomers on body fat mass in overweight humans. Obes Res. 2004;12:591-8.

21. Atkinson RL. Conjugated linoleic acid for altering body composition and treating obesity. In: Yurawecz MP, Mossoba MM, Kramer JKG, Pariza MW, and Nelson GJ, eds. Advances in conjugated linoleic acid research. Vol 1. Champaign, IL: AOCS Press, 1999: 348-353.

22. Kreider RB, Ferreira MP, Greenwood M, Wilson M, Almada AL. Effects of conjugated linoleic acid supplementation during resistance training on body composition, bone density, strength, and selected hematological markers. J Strength Cond Res. 2002;16:325-34.

23. Riserus U, Vessby B, Arnlov J, Basu S. Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. Am J ClinNutr. 2004;80:279-83.

24. Petridou A, Mougios V, Sagredos A. Supplementation with CLA: isomer incorporation into serum lipids and effect on body fat of women. Lipids. 2003;38:805-11.

25. Eyjolfson V, Spriet LL, Dyck DJ. Conjugated linoleic acid improves insulin sensitivity in young, sedentary humans. Med Sci Sports Exerc. 2004;36:814-20.

26. Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP. Conjugated linoleic acid impairs endothelial function. ArteriosclerThrombVasc. Biol. 2006;26:307-12.

27. Lambert EV, Goedecke JH, Bluett K, Heggie K, Claassen A, Rae DE, et al. Conjugated linoleic acid (CLA) vs. high-oleic acid sunflower oil: effects on energy metabolism, glucose tolerance, blood lipids, appetite and body composition in regularly exercising individuals. Br J Nutr.2007 (in press).

28. Gaullier JM, Halse J, Høye K, Kristiansen K, Fagertun H, Vik H, et al. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr. 2005;135:778-84.

29. Ogden CL, Fryar CD, Carroll MD, Flegal KM. Mean bodyweight, height, and body mass index, United States 1960–2002. Advance data from vital and health statistics; no. 347. Hyattsville, Maryland: National Center for Health Statistics, 2004.

30. Gaullier JM, Berven G, Blankson H, Gudmundsen O. Clinical trial results support a preference for using CLA preparations enriched with two isomers rather than four isomers in human studies. Lipids. 2002;37:1019-25.

31. Wang YW, Jones PJ. Conjugated linoleic acid and obesity control: efficacy and mechanisms. Int J ObesRelatMetabDisord. 2004;28:941-55.

32. Riserus U, Basu S, Jovinge S, Fredrikson GN, Arnlov J, Vessby B. Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. Circulation. 2002;106:1925-9.

33. Larsen TM, Toubro S, Gudmundsen O, Astrup A. Conjugated linoleic acid supplementation for 1 у does not prevent weight or body fat regain. Am J ClinNutr. 2006;83:606-12.

34. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-12.

35. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J ClinEpidemiol. 2001;54:316-22.

36. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci. 2002;23:360-6.

37. Musiek ES, Gao L, Milne GL, Han W, Everhart MB, Wang D, et al. Cyclopentenoneisoprostanes inhibit the inflammatory response in macrophages. J Biol Chem. 2005;280:35562-70.

38. Lee KN, Kritchevsky D, Pariza MW. Conjugated linoleic acid and atherosclerosis in rabbits.Atherosclerosis. 1994;108:19-25.

39. Kritchevsky D, Tepper SA, Wright S, Tso P, Czarnecki SK. Influence of conjugated linoleic acid (CLA) on establishment and progression of atherosclerosis in rabbits. J Am CollNutr. 2000;19:472S-7S.

40. Kritchevsky D, Tepper SA, Wright S, Czarnecki SK, Wilson ТА, Nicolosi RJ. Conjugated linoleic acid isomer effects in atherosclerosis: growth and regression of lesions. Lipids. 2004;39:611-6.

41.Whigham LD, Cook EB, Stahl JL, Saban R, Bjorling DE, Pariza MW, et al. CLA reduces antigen-induced histamine and PGE(2) release from sensitized guinea pig tracheae. Am J PhysiolRegulIntegr Comp Physiol. 2001 ;280:R908-12.

42. Whigham LD, Higbee A, Bjorling DE, Park Y, Pariza MW, Cook ME. Decreased antigen-induced eicosanoid release in conjugated linoleic acid-fed guinea pigs. Am J PhysiolRegulIntegr Comp Physiol. 2002;282:R1104-12.

43. Jaudszus A, Foerster M, Kroegel C, Wolf I, Jahreis G. Cis-9,trans-11- CLAexerts anti-inflammatory effects in human bronchial epithelial cells and eosinophils: comparison to trans-10,cis-12-CLA and to linoleic acid. BiochimBiophysActa. 2005;1737:111-8.

44. Yang M, Cook ME. Dietary CLA decreased weight loss and extended survival following the onset of kidney failure in NZB/W F1 mice. Lipids. 2003;38:21-4.

45. Butz D, Cook ME. CLA Modulated immune-induced cachexia after immunization with arthritogenic collagen type II. FASEB J 2002;16:A985.

46. Hontecillas R, Wannemeulher MJ, Zimmerman DR, Hutto DL, Wilson JH, Ahn DU, et al. Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. J Nutr. 2002;132:2019-27.

47. Miller CC, Park Y, Pariza MW, Cook ME. Feeding conjugated linoleic acid to animals partially overcomes catabolic responses due to endotoxin injection. BiochemBiophys Res Commun. 1994;198:1107-12.

48. Graves E, Hitt A, Pariza MW, Cook ME, McCarthy DO. Conjugated linoleic acid preserves gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. Res Nurs Health. 2005;28:48-55.

49. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. Am J ClinNutr. 2004;80:887-95.

50. Belury MA. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. Annu Rev Nutr. 2002;22:505-31.

References

1. Lenz M, Richter T, Mühlhauser I. The Morbidity and Mortality Associated With Overweight and Obesity in Adulthood. A Systematic Review.DeutschesÄrzteblatt International DtschArzteblInt 2009;106(40):641-8.

2. Butrova SA, Plokhaya AA. Lecheniyeozhireniya: sovremennyyeaspekty. RMZh. 2000;24(9):1140-6. Russian.

3. Chin SF, Liu W, Storkson JM, Ha YL, Pariza MW. Dietary sources of conjugated dienoic isomers of linoleic acid, a newly recognised class of anticarcinogens.J Food Compos Anal. 1992;5:185-97.

4. Pariza MW. Perspective on the safety and effectiveness of conjugated linoleic acid.Am J ClinNutr. 2004;79 (Suppl):1132S-6S.

5. Park Y, Albright KJ, Liu W, Storkson JM, Cook ME, Pariza MW. Effect of conjugated linoleic acid on body composition in mice.Lipids.1997; 32:853-8.

6. de Deckere EA, van Amelsvoort JM, McNeill GP, Jones P. Effects of conjugated linoleic acid (CLA) isomers on lipid levels and peroxisome proliferation in the hamster. Br J Nutr. 1999;82:309-17.

7. Park Y, Storkson JM, Albright KJ, Liu W, Pariza MW. Evidence that the trans-10,cis-12 isomer of conjugated linoleic acid induces body composition changes in mice. Lipids. 1999;34:235-41.

8. Gavino VC, Gavino G, Leblanc MJ, Tuchweber B. An isomeric mixture of conjugated linoleic acids but not pure cis-9, trans-11 -octadecadienoic acid affects body weight gain and plasma lipids in hamsters. J Nutr. 2000;130:27-9.

9. Pariza MW, Park Y, Cook ME. The biologically active isomers of conjugated linoleic acid.Prog Lipid Res. 2001;40:283-98.

10. Whigham Leah D, Watras Abigail C, Schoeller, Dale A. Efficacy of conjugated linoleic acid for reducing fat mass: a meta-analysis in humans. Am J ClinNutr. 2007;85:1203-11.

11. Blankson H, Stakkestad JA, Fagerton H, Thorn E, Wadstein J, Gudmundsen 0. Conjugated linoleic acid reduces body fat mass in overweight and obese humans. J Nutr. 2000;130:2943-8.

12. Gaullier JM, Halse J, Hoye K, Kristiansen K, Fagertun H, Vik H, et al. Conjugated linoleic acid supplementation for 1 у reduces body fat mass in healthy overweight humans. Am J ClinNutr. 2004;79:1118-25.

13. Mougios V, Matsakas A, Petridou A, Ring S, Sagredos A, Melissopoulou A, et al. Effect of supplementation with conjugated linoleic acid on human serum lipids and body fat. J Nutr.Biochem. 2001;12:585-94.

14. Smedman A, Vessby B. Conjugated linoleic acid supplementation in humans-metabolic effects. Lipids. 2001;36:773-81.

15. Gaullier JM, Halse J, Høivik HO, Høye K, Syvertsen C, Nurminiemi M, et al. Six months supplementation with conjugated linoleic acid (CLA) induces regional-specific fat mass decreases in overweight and obese. Br J Nutr. 2007;97:50-60.

16. Watras AC, Buchholz AC, Close RN, Zhang Z, Schoeller DA. The role of conjugated linoleic acid in reducing body fat and preventing holiday weight gain.Int J Obesity. 2007;31:481-7.

17. Pinkoski C, Chilibeck PD, Candow DG, Esliger D, Ewaschuk JB, Facci M, et al. The effects of conjugated linoleic acid supplementation during resistance training.Med Sci Sports.Exerc. 2006;38:339-48.

18. Berven G, Bye A, Hals O, et al. Safety of conjugated linoleic acid (CLA) in overweight or obese human volunteers. Eur J Lipid Sci Technol. 2000;102:455-62.

19. Riserus U, Arner P, Brismar K, Vessby B. Treatment with dietary trans10cis12 conjugated linoleic acid causes isomer-specific insulin resistance in obese men with the metabolic syndrome. Diabetes Care. 2002;25:1516-21.

20. Malpuech-Brugere C, Verboeket-van de Venne WP, Mensink RP, Arnal MA, Morio B, Brandolini M, et al. Effects of two conjugated linoleic acid isomers on body fat mass in overweight humans. Obes Res. 2004;12:591-8.

21. Atkinson RL. Conjugated linoleic acid for altering body composition and treating obesity. In: Yurawecz MP, Mossoba MM, Kramer JKG, Pariza MW, and Nelson GJ, eds. Advances in conjugated linoleic acid research. Vol 1. Champaign, IL: AOCS Press, 1999: 348-353.

22. Kreider RB, Ferreira MP, Greenwood M, Wilson M, Almada AL. Effects of conjugated linoleic acid supplementation during resistance training on body composition, bone density, strength, and selected hematological markers. J Strength Cond Res. 2002;16:325-34.

23. Riserus U, Vessby B, Arnlov J, Basu S. Effects of cis-9,trans-11 conjugated linoleic acid supplementation on insulin sensitivity, lipid peroxidation, and proinflammatory markers in obese men. Am J ClinNutr. 2004;80:279-83.

24. Petridou A, Mougios V, Sagredos A. Supplementation with CLA: isomer incorporation into serum lipids and effect on body fat of women. Lipids. 2003;38:805-11.

25. Eyjolfson V, Spriet LL, Dyck DJ. Conjugated linoleic acid improves insulin sensitivity in young, sedentary humans. Med Sci Sports Exerc.2004; 36:814-20.

26. Taylor JS, Williams SR, Rhys R, James P, Frenneaux MP. Conjugated linoleic acid impairs endothelial function. ArteriosclerThromb Vase.Biol. 2006; 26:307-12.

27. Lambert EV, Goedecke JH, Bluett K, Heggie K, Claassen A, Rae DE, et al. Conjugated linoleic acid (CLA) vs. high-oleic acid sunflower oil: effects on energy metabolism, glucose tolerance, blood lipids, appetite and body composition in regularly exercising individuals. Br J Nutr.2007 (in press).

28. Gaullier JM, Halse J, Høye K, Kristiansen K, Fagertun H, Vik H, et al. Supplementation with conjugated linoleic acid for 24 months is well tolerated by and reduces body fat mass in healthy, overweight humans. J Nutr. 2005;135:778-84.

29. Ogden CL, Fryar CD, Carroll MD, Flegal KM. Mean bodyweight, height, and body mass index, United States 1960–2002. Advance data from vital and health statistics; no. 347. Hyattsville, Maryland: National Center for Health Statistics, 2004.

30. Gaullier JM, Berven G, Blankson H, Gudmundsen O. Clinical trial results support a preference for using CLA preparations enriched with two isomers rather than four isomers in human studies. Lipids. 2002;37:1019-25.

31. Wang YW, Jones PJ. Conjugated linoleic acid and obesity control: efficacy and mechanisms. Int J ObesRelatMetabDisord. 2004;28:941-55.

32. Riserus U, Basu S, Jovinge S, Fredrikson GN, Arnlov J, Vessby B. Supplementation with conjugated linoleic acid causes isomer-dependent oxidative stress and elevated C-reactive protein: a potential link to fatty acid-induced insulin resistance. Circulation. 2002;106:1925-9.

33. Larsen TM, Toubro S, Gudmundsen O, Astrup A. Conjugated linoleic acid supplementation for 1 у does not prevent weight or body fat regain. Am J ClinNutr. 2006;83:606-12.

34. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 2003;111:1805-12.

35. Brown DW, Giles WH, Croft JB. White blood cell count: an independent predictor of coronary heart disease mortality among a national cohort. J ClinEpidemiol. 2001;54:316-22.

36. Cracowski JL, Durand T, Bessard G. Isoprostanes as a biomarker of lipid peroxidation in humans: physiology, pharmacology and clinical implications. Trends Pharmacol Sci. 2002;23:360-6.

37. Musiek ES, Gao L, Milne GL, Han W, Everhart MB, Wang D, et al. Cyclopentenoneisoprostanes inhibit the inflammatory response in macrophages. J Biol Chem. 2005;280:35562-70.

38. Lee KN, Kritchevsky D, Pariza MW. Conjugated linoleic acid and atherosclerosis in rabbits.Atherosclerosis. 1994;108:19-25.

39. Kritchevsky D, Tepper SA, Wright S, Tso P, Czarnecki SK. Influence of conjugated linoleic acid (CLA) on establishment and progression of atherosclerosis in rabbits. J Am CollNutr. 2000;19:472S-7S.

40. Kritchevsky D, Tepper SA, Wright S, Czarnecki SK, Wilson ТА, Nicolosi RJ. Conjugated linoleic acid isomer effects in atherosclerosis: growth and regression of lesions. Lipids. 2004;39:611-6.

41. Whigham LD, Cook EB, Stahl JL, Saban R, Bjorling DE, Pariza MW, et al. CLA reduces antigen-induced histamine and PGE(2) release from sensitized guinea pig tracheae. Am J PhysiolRegulIntegr Comp Physiol. 2001 ;280:R908-12.

42. Whigham LD, Higbee A, Bjorling DE, Park Y, Pariza MW, Cook ME. Decreased antigen-induced eicosanoid release in conjugated linoleic acid-fed guinea pigs. Am J PhysiolRegulIntegr Comp Physiol. 2002;282:R1104-12.

43. Jaudszus A, Foerster M, Kroegel C, Wolf I, Jahreis G. Cis-9,trans-11-CLAexerts anti-inflammatory effects in human bronchial epithelial cells and eosinophils: comparison to trans-10,cis-12-CLA and to linoleic acid. BiochimBiophysActa. 2005;1737:111-8.

44. Yang M, Cook ME. Dietary CLA decreased weight loss and extended survival following the onset of kidney failure in NZB/W F1 mice. Lipids. 2003;38:21-4.

45. Butz D, Cook ME. CLA Modulated immune-induced cachexia after immunization with arthritogenic collagen type II. FASEB J 2002;16:A985.

46. Hontecillas R, Wannemeulher MJ, Zimmerman DR, Hutto DL, Wilson JH, Ahn DU, et al. Nutritional regulation of porcine bacterial-induced colitis by conjugated linoleic acid. J Nutr. 2002;132:2019-27.

47. Miller CC, Park Y, Pariza MW, Cook ME. Feeding conjugated linoleic acid to animals partially overcomes catabolic responses due to endotoxin injection. BiochemBiophysResCommun. 1994;198:1107-12.

48. Graves E, Hitt A, Pariza MW, Cook ME, McCarthy DO. Conjugated linoleic acid preserves gastrocnemius muscle mass in mice bearing the colon-26 adenocarcinoma. Res Nurs Health. 2005;28:48-55.

49. Moloney F, Yeow TP, Mullen A, Nolan JJ, Roche HM. Conjugated linoleic acid supplementation, insulin sensitivity, and lipoprotein metabolism in patients with type 2 diabetes mellitus. Am J ClinNutr. 2004;80:887-95.

50. Belury MA. Dietary conjugated linoleic acid in health: physiological effects and mechanisms of action. AnnuRevNutr. 2002;22:505-31.

reduxin-light.ru

Reduxin Light is a new generation product, the main action of which is aimed at burning fat cells. Before talking about this tool, I would like to note immediately that there are two drugs on the market with similar names – “Reduxin Light” and “Reduxin”.Confound them in no case impossible!

Just Reduxin is a drug that is prescribed only by doctors and is designed to treat obesity. Its active component is the sutractin, which affects the work of the central nervous system. Therefore, you can not take Reduxin without evidence.

Reduxin Light for weight loss is a dietary supplement that has a slightly different effect on the body. It also promotes weight loss, but at a different level, without affecting the central nervous system.

Redoxin Light:

composition The main active substance of this drug is conjugated linoleic acid( CLA), which is responsible for regulating the metabolism of fats and carbohydrates, preventing their deposition in

the body. At the same time, it passes glucose into muscle tissue and converts it into energy, which is enough for the body to function properly.

In addition, this drug contains in its composition a large amount of vitamin E or, as it is also called, tocopherol. It protects the cells of the body from oxidation and prevents their death. In this vitamin absolutely all tissues and organs of our body are needed. It provides them with oxygen and positively affects the coagulability of the blood, thereby preventing the formation of blood clots in the vessels.

Vitamin E is also known for its rejuvenating effect. It perfectly moisturizes the skin, improves the condition of the hair and nails. Therefore, taking Reduxina Light will help you not only lose excess weight, but generally improve the appearance.

How do I take the drug?

Take Reduxin Light only after consulting a doctor. He will determine the necessary dosage of the drug, because, first of all, it depends on the initial weight. The more weight, the greater the dosage.

As the manufacturer says, Reduxin Light needs to take 1-2 capsules during meals. Take the drug you need courses lasting 2 months. A year is recommended for 4 courses.

The price of this drug is different and depends on how many capsules are contained in one package.30 tablets cost about 750 rubles, 90 capsules – 1500 rubles. The drug is not cheap. Annual treatment is not cheap. However, according to the reviews, it costs such money.

The drug really helps to lose weight, without much effort. The main thing is to observe the rules of its application and to refuse from sweets, buns and other food products, which contain a lot of carbohydrates.

Contraindications and side effects of

It should be noted that Reduxin Light has contraindications, therefore it may not be used by all.

It can not be taken by persons who have not reached the age of 18, as well as women who are at the stage of pregnancy and lactation. The substances included in this preparation can provoke the development of an allergic reaction. There are no other side effects of Reduxina Light, but this does not mean that it can be taken uncontrollably. Therefore, carefully read the instructions and consult with an expert.

Reduxin Light: the opinion of specialists

Doctors-nutritionists constantly follow the novelties that appear in pharmacies marked “for weight loss.”They are easy to understand in these preparations and one composition can determine their effectiveness. Therefore, their opinion still need to listen.

As for Reduxin Light itself, it’s not strange, doctors are more loyal to this drug. In their opinion, it contains harmless substances that, even if they do not lead to the desired effect, can not do much harm.

Doctors say that the most important component of this drug is CLC, which we mentioned above. In their opinion, it is his deficiency in the body that leads to obesity.

However, just so, replenishing the reserves of the CLC, a person will not be able to overcome excess weight. Without a special diet and exercise, it will not be possible to get close to your goal by a single step. Therefore, there is no need to believe in a miracle.

Reduxin Light is an ordinary dietary supplements, which are now full on the market. All of them are effective in their own way, but they are all safe. Reduxin Light is an absolutely safe biologically active additive, which almost everyone can take.

It should be noted that it is also required to adhere to all those recommendations that the manufacturer gives on the use of his drug. Be sure to take breaks between meals and adhere to proper nutrition even during the “pause”.

Video for Slimming Weight Reduction

simhealths.com

Producer: Federal State Unitary Enterprise Moscow Endocrine Plant Russia

Code of automatic telephone exchange: A08A

Release form: Firm dosage forms. Capsules.

Indications to use: Obesity.


General characteristics. Structure:

Active ingredient: 10 mg or 15 mg of a sibutramin of a hydrochloride of monohydrate, 153,5 mg or 158,5 mg of cellulose microcrystallic in 1 capsule.

Excipients: calcium stearate.

Structure of the capsule: titanium dioxide, dye azoruby, dye diamond blue or blue patent, gelatin.

Pharmacological properties:

Pharmacodynamics. Редуксин® – the combined drug which effect is caused by the components which are its part. Sibutramin is pro-medicine and shows the action of in vivo at the expense of metabolites (primary and secondary amines) inhibiting the return capture of monoamines (serotonin, noradrenaline and dopamine). Increase in contents in synapses of neurotransmitters increases activity of the central 5HT-serotoninovy and adrenergic receptors that promotes increase in feeling of saturation and decrease in food requirement, and also increase in thermoproducts. Indirectly activating beta3-adrenoceptors, сибутрамин influences brown fatty tissue.

Decrease in body weight is followed by increase in concentration in a blood plasma of lipoproteins of the high density (LPVP) and reduction in the amount of triglycerides, the general cholesterol, lipoproteins of the low density (LPNP) and uric acid. Sibutramin and his metabolites do not influence release of monoamines, do not inhibit a monoaminooxidase (MAO); have low affinity to a large number of neuromediator receptors, including serotoninovy (5-HT1, 5-Nt1a, 5-HT1B, 5-HT2C), adrenergic (beta1, beta2, beta3, alfa1, alfa2), dopamine (D1, D2), muskarinovy, histamine (H1), benzodiazepine and glutamate (NMDA) receptors. Cellulose microcrystallic is enterosorbents, has sorption properties and nonspecific disintoxication action.

Connects and brings out of an organism various microorganisms, products of their life activity, toxins of the exogenous and endogenous nature, allergens, xenobiotics, and also surplus of some metabolic products and metabolites responsible for development of endogenous toxicosis.

Pharmacokinetics. After intake it is quickly soaked up from the digestive tract (DT) not less than for 77%. At “primary passing” through a liver is exposed to biotransformation under the influence of CYP3A4 isoenzyme with formation of two active metabolites (монодесметилсибутрамин (M1) and дидесметилсибутрамин (Sq.m)). After reception of a single dose of 15 mg the maximum concentration in a blood plasma (Cmax) M1 makes 4 ng/ml (3,2-4,8 ng/ml), Sq.m — 6,4 ng/ml (5,6-7,2 ng/ml). Cmax is reached in 1,2 h (сибутрамин), 3-4 h (M1 and Sq.m). The concomitant use of food lowers Cmax of metabolites for 30% and increases time of its achievement for 3 h, without changing the area under a curve “concentration time” (AUC).

It is quickly distributed on fabrics. Communication with proteins makes 97% (сибутрамин) and 94% (M1 and Sq.m). Equilibrium concentration of active metabolites in a blood plasma is reached within 4 days after the beginning of use and turns concentration in a blood plasma approximately twice after reception of a single dose. An elimination half-life of a sibutramin – 1,1 h, M1 – 14 h, Sq.m – 16 h. Active metabolites are exposed to a hydroxylation and conjugation with formation of inactive metabolites which are removed preferential by kidneys.

The limited data which are available now do not indicate existence of clinically significant distinctions in pharmacokinetics at men and women.

The pharmacokinetics at elderly healthy faces (average age of 70 years) is similar that at young people.

Renal failure. The renal failure has no effect on AUC of active metabolites M1 and Sq.m, except the Sq.m metabolite at the patients with an end-stage of a renal failure who are on dialysis.

Liver failure. Patients with a moderate liver failure after a single dose have a sibutramina of AUC of active metabolites of M1 and Sq.m 24% higher, than at healthy faces.

Indications to use:

Редуксин® it is shown for decrease in body weight at the following states:

• alimentary obesity with the body weight index (BWI) of 30 kg/sq.m and more;• alimentary obesity with an index of the body weight of 27 kg/sq.m and more in combination with a diabetes mellitus 2 types and a dislipidemiya.

Route of administration and doses:

Редуксин® is accepted in 1 times a day. The dose is established individually, depending on portability and clinical performance.

The initial dose of 10 mg/days is recommended, at bad portability reception of 5 mg/days is possible. Capsules should be accepted in the morning, without chewing and washing down with enough liquid (a glass of water). Drug can be accepted as on an empty stomach, and to combine with meal. If within 4 weeks from an initiation of treatment decrease in body weight less than 2 kg is not reached, then the dose increases to 15 mg/days.

Treatment by the drug Reduksin® should not continue more than 3 months at patients who insufficiently well react to therapy i.e. which within 3 months of treatment do not manage to reach decrease in body weight by 5% of an initial indicator.

Treatment should not be continued if at further therapy, after the reached decrease in body weight, the patient adds in the body weight of 3 kg and more again. Duration of treatment should not exceed 1 years as concerning more long period of reception of a sibutramin data on efficiency and safety are absent.

Treatment by the drug Reduksin® has to be performed in a complex with a diet and physical exercises under control of the doctor having practical experience of treatment of obesity.

Features of use:

Use during pregnancy and breastfeeding. As so far there is no rather large number of researches concerning safety of impact of a sibutramin on a fruit, this drug is contraindicated during pregnancy. The women who are in reproductive age during administration of drug of Reduksin® have to use contraceptive means. It is contraindicated to accept Reduksin® during breastfeeding.

Редуксин® it is necessary to apply only when all non-drug actions for decrease in body weight are ineffective – if decrease in body weight within 3 months made less than 5 kg.

Treatment by the drug Reduksin® has to be performed within complex therapy on decrease in body weight under control of the doctor having practical experience of treatment of obesity. Complex therapy includes both change of a diet and a way of life, and increase in physical activity. An important component of therapy is creation of premises to permanent change of a feeding behavior and a way of life which are necessary for preservation of the reached decrease in body weight and after cancellation of medicamentous therapy. Patients need to change within therapy by the drug Reduksin® the way of life and habits so that after completion of treatment to provide preservation of the reached body degrowth.

Patients have to have a clear view that non-compliance with these requirements will lead to repeated increase in body weight and repeated addresses to the attending physician. At the patients accepting Reduksin® it is necessary to measure the arterial pressure and heart rate regularly. In the first 3 months of treatment it is necessary to control these parameters each 2 weeks, and then monthly. If during two visits increase in heart rate at rest of ≥10 beats per minute or the systolic/diastolic pressure of ≥10 mm hg in a row comes to light, it is necessary to stop treatment.

At patients with arterial hypertension at whom against the background of hypotensive therapy arterial pressure is higher than 145/90 mm hg this control has to be carried out especially carefully and, if necessary, through shorter intervals. At patients at whom arterial pressure twice at repeated measurement exceeded the level of 145/90 mm hg treatment by the drug Reduksin® has to be cancelled (See the section “Side effect”).

At patients with an apnoea syndrome in a dream it is necessary to control arterial pressure especially carefully.

The special attention is required by co-administration of the drugs increasing QT interval. Treat these drugs H1-gistaminoblokatory (астемизол, терфенадин); the antiarrhytmic drugs increasing QT interval (Amiodaronum, quinidine, флекаинид, мексилетин, пропафенон, соталол); stimulator of motility of a gastrofinal path цизаприд; Pimozidum, сертиндол and tricyclic antidepressants. It concerns also states which are capable to lead to increase in an interval of QT, such as, a hypopotassemia and a hypomagnesiemia. (See also section “Interaction with Other Medicines”).

The interval between reception of MAO inhibitors (including furasolidone, Procarbazinum, a selegilin) and the drug Reduksin® has to make not less than 2 weeks.

Though connection between administration of drug of Reduksin® and development of primary pulmonary hypertensia is not established, however, considering well-known risk of drugs of this group, at regular medical control it is necessary to pay special attention to such symptoms as progressing диспноэ (breath disturbance), thorax pain and hypostases standing.

At the admission of a dose of the drug Reduksin® it is not necessary to accept a double dose of drug in the following reception, it is recommended to continue further administration of drug according to the ordered scheme.

Duration of administration of drug of Reduksin® should not exceed 1 years.

At joint reception of a sibutramin and other inhibitors of the return serotonin reuptake there is an increased risk of development of bleedings. At the patients predisposed to bleedings, and also accepting the drugs influencing a hemostasis or function of thrombocytes сибутрамин it is necessary to apply with care.

Though clinical data on accustoming to a sibutramin are absent, it is necessary to find out whether was in the anamnesis of the patient of cases of medicinal dependence and to pay attention to possible signs of abuse of medicines.

Influence on ability to control of vehicles and mechanisms. Administration of drug of Reduksin® can limit ability to control of vehicles and mechanisms. During use of the drug Reduksin® it is necessary to be careful at control of vehicles and occupation other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions.

Side effects:

Most often side effects arise in an initiation of treatment (in the first 4 weeks). Their expressiveness and frequency weaken eventually. Side effects carry, in general, not difficult and reversible difficult character. Side effects, depending on impact on bodies and systems of bodies, are presented in the following order: very often (> 10%), it is frequent (≥ 1%, but ≤ 10%).

From the central nervous system very frequent side effects are dryness in a mouth and sleeplessness, the headache, dizziness, concern, paresthesias, and also taste change are often noted.

From cardiovascular system tachycardia, a heart consciousness, increase in arterial pressure, a vazodilatation often meet.

From system of digestive organs loss of appetite and a lock, often nausea and an exacerbation of hemorrhoids are very often observed. At tendency to locks in the first days control of evakuatorny function of intestines is necessary. At emergence of a lock reception is stopped and accept laxative.

From integuments the increased sweating is often noted. In isolated cases at treatment sibutraminy the following undesirable clinically significant phenomena are described: a dysmenorrhea, hypostases, a grippopodobny syndrome, a skin itch, a dorsodynia, an abdominal pain, paradoxical increase in appetite, thirst, rhinitis, a depression, drowsiness, emotional lability, uneasiness, irritability, nervousness, acute intersticial nephrite, bleedings, Shenleyn-Genokh’s purpura (hemorrhages in skin), spasms, thrombocytopenia, tranzitorny increase in activity of “hepatic” enzymes in blood.

Changes of cardiovascular system. Moderate rise in arterial pressure at rest upon 1 – 3 mm hg and moderate increase in pulse by 3 – 7 beats per minute is observed. In some cases more expressed increases in arterial pressure and heart rate are not excluded. Clinically significant changes of arterial pressure and pulse are registered preferential in an initiation of treatment (in the first 4 – 8 weeks).

Use of the drug Reduksin® for patients with the increased arterial pressure: watch the section “Contraindications” and “Special Instructions”. During the post-market researches the additional side reactions which are listed below on systems of bodies were described:

From cardiovascular system: ciliary arrhythmia.

From immune system: hypersensitivity reactions (from a moderate enanthesis and a small tortoiseshell to a Quincke’s disease (Quincke’s edema) and an anaphylaxis).

Mental disorders: psychosis, states suitsidalno the directed thinking, a suicide and a mania. At emergence of similar states drug needs to be cancelled.

From a nervous system: spasms, short-term disturbances of memory.

From an organ of sight: sight misting (“veil before eyes”).

From system of digestive organs: diarrhea, vomiting.

From skin and hypodermic cellulose: alopecia.

From kidneys and urinary tract: ischuria.

From reproductive system: disturbances of an ejaculation/orgasm, impotence, disturbance of a menstrual cycle, uterine bleedings.

Interaction with other medicines:

Inhibitors of a microsomal oxidation, including CYP3A4 isoenzyme inhibitors (кетоконазол, erythromycin, cyclosporine, etc.) raise in a blood plasma of concentration of metabolites of a sibutramin with increase in heart rate and clinically insignificant increase in an interval of QT. Rifampicin, antibiotics from group of macroleads, Phenytoinum, carbamazepine, phenobarbital and dexamethasone can accelerate metabolism of a sibutramin.

Simultaneous use of several drugs increasing the content of serotonin in a blood plasma can lead to development of serious interaction. The so-called serotoninovy syndrome can develop in rare instances at simultaneous use of the drug Reduksin® with selective serotonin reuptake inhibitors (drugs for treatment of a depression), with some drugs for treatment of migraine (суматриптан, dihydroergotamine), with strong analgetics (pentazocine, pethidine, fentanyl), or antibechic drugs (dextromethorphan).

Sibutramin does not influence action of peroral contraceptive means.

At a concomitant use of a sibutramin and alcohol strengthening of negative effect of alcohol was not noted. However alcohol is not combined with the dietary actions recommended at reception of a sibutramin at all.

At simultaneous use with sibutraminy other drugs influencing a hemostasis or function of thrombocytes the risk of development of bleedings increases.

Medicinal interaction at simultaneous use of a sibutramin with the drugs increasing the arterial pressure and heart rate is insufficiently fully studied now. This group of drugs includes decongestants, antibechic, anti-cold and antiallergic drugs which part ephedrine or pseudoephedrine are. Therefore in cases of a concomitant use of these drugs with sibutraminy it is necessary to be careful.

Combined use of a sibutramin with the drugs for decrease in body weight operating on the central nervous system or drugs for treatment of mental disorders contraindicated.

Contraindications:

– the established hypersensitivity to a sibutramin or to other components of drug;

– existence of the organic reasons of obesity (for example, hypothyroidism);- serious violations of food — nervous anorexia or nervous bulimia;- mental diseases;- syndrome Gilles de la Turetta (generalized tics);- a concomitant use of MAO inhibitors (for example, phentermine, a fenfluramin, a deksfenfluramin, ethylamphetamine, ephedrine) or use within 2 weeks before administration of drug of Reduksin® and 2 weeks after the end of its reception of other drugs operating on the central nervous system, inhibiting the return serotonin reuptake (for example, antidepressants, neuroleptics); the somnolent drugs containing tryptophane and also other drugs of the central action for decrease in body weight or for treatment of mental disorders;- cardiovascular diseases (in the anamnesis and now): coronary heart disease (myocardial infarction (MI), stenocardia); chronic heart failure in decompensation stages, okklyuziruyushchy diseases of peripheral arteries, tachycardia, arrhythmia, cerebrovascular diseases (a stroke, tranzitorny disturbances of cerebral circulation);- uncontrollable arterial hypertension (the arterial pressure (AP) is higher than 145/90 mm hg) (see also section “Special Instructions”);- thyrotoxicosis;- heavy abnormal liver functions and/or kidneys;- benign hyperplasia of a prostate;- pheochromocytoma;- closed-angle glaucoma;- the established pharmacological, drug or alcohol addiction;- pregnancy and period of breastfeeding;- the age up to 18 years is also more senior than 65 years.

With care it is necessary to appoint drug at the following states: arrhythmias in the anamnesis, chronic insufficiency blood circulation, diseases of coronary arteries (including in the anamnesis), except coronary heart disease (to THEM, stenocardia); to glaucoma, except closed-angle glaucoma, a cholelithiasis, arterial hypertension (controlled and in the anamnesis), neurologic disturbances, including a delay of intellectual development and a spasm (including in the anamnesis), epilepsy, an abnormal liver function and/or kidneys easy and moderate severity, motor and verbal tics in the anamnesis, tendency to bleeding, disturbance of coagulability of blood, the administration of drugs influencing a hemostasis or function of thrombocytes.

Overdose:

There are extremely limited data on an occasion of overdose of a sibutramin. The most often found adverse reactions connected with overdose: tachycardia, increase in arterial pressure, headache, dizziness. It is necessary to inform the attending physician in case of alleged overdose.

Special treatment and specific antidotes does not exist. It is necessary to carry out the general actions: to provide free breath, to watch a condition of cardiovascular system, and also, if necessary, to perform the supporting symptomatic therapy. Timely use of absorbent carbon, and also a gastric lavage can reduce receipt of a sibutramin in an organism.

Patients with the increased arterial pressure and tachycardia can appoint beta adrenoblockers. Efficiency of an artificial diuresis or hemodialysis is not established.

Storage conditions:

In the place protected from light at a temperature not above 25 °C. Drug should be stored in the places unavailable to children. Sibutramin treats the List of strong substances approved by the Resolution of the Government of the Russian Federation of 29.12.2007 No. 964. A period of validity – 3 years. Not to apply after a period of validity.

Issue conditions:

According to the recipe

Packaging:

Firm gelatin capsules. On 7, 10, 14 or 15 capsules in a blister strip packaging from the film of PVC and printing aluminum foil varnished. 1, 2, 3, 4, 6, 8, 9,10, 12, 15, 16, 18 or 20 blister strip packagings together with the application instruction place in a pack from a cardboard.

en.medicalmeds.eu

Reviews of doctors about the reduction for weight loss

Reviews of doctors about the reduction for weight loss in most positive. With a proper appointment, the drug “fulfills” the promised promises: it strengthens the feeling of satiety, dulls hunger, which leads to a gradual, but rather rapid weight loss. According to reviews, nutritionists note such positive aspects of the reduction for weight loss:

  • almost all of those who lose weight become dull of appetite,
  • the drug gives fast and most stable results;
  • not addictive;
  • forms the right dietary behavior for those who want to lose weight.

Nutritionists insist on two important points: that in a patient who is prescribed a reduction for weight loss, there was no history of organic causes of excess weight, and that the treatment was carried out by an experienced doctor who professes an individual approach to every person who wants to get rid of obesity.

Reviews of those who lose weight about the weight reduction reducer

Reviews thin with a reduction for weight loss are contradictory. Some note that the drug perfectly helps to adhere to the diet, because it reduces appetite, eliminates the desire to eat fatty, fried, sweet and other forbidden dishes. According to reviews, moderate appetite persists after discontinuing the reduction, helping the patient to develop and consolidate the right habits and diet. One woman, for example, lost 12 kilograms of weight within three months.

Others, on the contrary, emphasize a lot of contraindications and possible risks for people with diseased kidneys, heart, liver. Some people have insomnia, irritability. Complaints also apply to the high price of the medication.

Analogs weight reduction reducer

Analogs reduction slimming –

  • goldline,
  • lindax,
  • meridia,
  • slimy.

Belong to pharmaceuticals against obesity, with an active substance, as in the reduction for weight loss, – sibutramine. A person loses weight due to a feeling of satiety. The desire to eat decreases, the thermal production increases.

The process of losing weight is accompanied by positive changes in lipid metabolism and blood composition in patients with dyslipidemia and type 2 diabetics, so the drug is shown in this category of patients.

According to the annotations, there are no significant differences between the analogues. All of them are issued in capsules, and pharmacy institutions are released according to medical prescriptions. Two to three years are stored, at 25 degrees (lindaksa – up to 30 degrees).

Reduxin is a popular remedy for weight loss, but not a panacea. It is effective in the framework of a set of measures that must be carried out under the supervision of a competent doctor in these matters. No less important components of treatment are proper nutrition and a healthy lifestyle. The patient needs to change his life so that the achieved result is maintained even after the withdrawal of the reduction for weight loss.

!

Found an error? Select it and press Ctrl + Enter.

iliveok.com

Leave a Reply

Your email address will not be published. Required fields are marked *